Symptom-Based Dosing Reduces Discharge Time in Neonatal Opioid Withdrawal

Optimizing Pharmacologic Management in Neonatal Opioid Withdrawal

The clinical management of neonatal opioid withdrawal syndrome remains a significant challenge for pediatricians as intrauterine opioid exposure continues to affect a substantial number of births [1, 2]. While non-pharmacological interventions are the preferred first line of care, many infants eventually require medication to manage moderate to severe withdrawal symptoms [3, 4]. Traditional pharmacologic protocols typically rely on scheduled opioid tapers using methadone or buprenorphine to gradually wean the infant [5, 6]. However, these rigid schedules may not always align with the fluctuating severity of an individual infant's symptoms, potentially prolonging the duration of treatment and hospitalization [3, 7]. In a multicenter, cluster, crossover randomized clinical trial involving 626 infants, researchers found that symptom-based dosing significantly reduced the mean time to medical readiness for discharge to 9.18 days compared to 11.61 days in the scheduled taper group (adjusted mean ratio, 0.79; 95% CI, 0.65 to 0.96) [3]. This approach adjusts medication based on the Eat, Sleep, Console assessment, a clinical tool prioritizing an infant's ability to function over a checklist of physical withdrawal signs, suggesting that flexible dosing may accelerate recovery and free up critical neonatal intensive care resources [3].

Trial Design and Patient Characteristics

To evaluate pharmacologic strategies for neonatal opioid withdrawal syndrome, researchers conducted a cluster, crossover randomized clinical trial with a run-in period across 23 US hospitals. In this specific study design, entire hospitals rather than individual patients were randomized to a sequence of interventions, allowing investigators to compare symptom-based dosing against a traditional scheduled opioid taper in real-world clinical environments. To ensure the study was adequately powered to detect differences in the primary outcome of medical readiness for discharge, the investigators performed sample size analyses between August 1, 2024, and September 23, 2024. The trial enrolled 626 infants at risk for requiring pharmacologic treatment. All participants met the inclusion criterion of a gestational age at birth of at least 36 weeks, with the cohort demonstrating a mean (SD) gestational age of 38 (1) weeks. Among the enrolled infants, 49% were male. Enrollment occurred between March 25, 2024, and April 9, 2025, and the final three-month assessment was completed on July 15, 2025. This multicenter approach across diverse clinical settings provided a robust sample to assess how different medication weaning protocols influence the timing of clinical recovery in late preterm and term neonates.

Comparing Care Models and Dosing Strategies

The study evaluated the impact of dosing strategies within two distinct clinical frameworks for managing neonatal opioid withdrawal syndrome. A total of 15 hospitals utilized the Eat, Sleep, Console approach, a functional assessment model that prioritizes non-pharmacologic interventions and evaluates an infant's basic ability to feed, rest, and be soothed rather than focusing solely on physical signs of withdrawal. Conversely, 8 hospitals employed Finnegan-based care, a traditional approach that relies on a comprehensive scoring system to quantify the severity of withdrawal symptoms across multiple physiological domains. By incorporating both care models, the researchers assessed how symptom-based dosing performed across different institutional environments. To compare the two pharmacologic approaches, the 23 US hospitals were randomized to one of two intervention sequences. The first sequence required sites to implement symptom-based dosing followed by a scheduled opioid taper, while the second sequence utilized a scheduled opioid taper followed by symptom-based dosing. This crossover design allowed each site to serve as its own control, minimizing the influence of hospital-specific practices on the results. Throughout the trial, opioid dosing was strictly guided by study-approved, site-specific algorithms that utilized the hospital's preferred primary opioid. This ensured that medication triggers remained consistent with the study protocol while allowing for local variation in the choice of pharmacologic agent.

Primary Outcomes in the Eat, Sleep, Console Cohort

The primary outcome cohort consisted of 383 infants managed using the Eat, Sleep, Console approach. Within this group, the researchers observed a significant reduction in the duration of treatment required before an infant reached clinical stability. Specifically, the mean time to medical readiness for discharge was 9.18 days for infants receiving symptom-based dosing, compared to 11.61 days for those managed with a scheduled opioid taper. This difference represents an adjusted mean ratio of 0.79 (95% CI, 0.65-0.96). For practicing pediatricians, this indicates that a symptom-based strategy can effectively accelerate the timeline for clinical stabilization, potentially reducing the infant's overall exposure to opioids. Beyond the timing of medical readiness, the study examined whether the dosing strategy influenced the likelihood of requiring medication or the total duration of the hospital stay. There was no significant difference in the risk for initiation of pharmacologic treatment between the two groups, with rates of 0.4 in the symptom-based group and 0.41 in the scheduled taper group (adjusted risk ratio, 0.99 [95% CI, 0.77-1.27]). Furthermore, while the time to medical readiness was shorter with symptom-based dosing, the overall length of stay in the Eat, Sleep, Console cohort did not show a statistically significant difference, measuring 10.91 days for symptom-based dosing versus 12.09 days for the scheduled taper (adjusted mean ratio, 0.9 [95% CI, 0.72-1.13]). These findings suggest that while symptom-based dosing optimizes the physiological weaning process, administrative or social factors may continue to influence the total time an infant remains in the hospital.

Secondary Outcomes and Clinical Safety

The researchers also evaluated a planned secondary outcome cohort of 243 infants managed using Finnegan-based care. In this group, the transition to symptom-based dosing did not yield the same statistical advantages observed in the Eat, Sleep, Console cohort. Specifically, the time to medical readiness for discharge was 15.99 days for the symptom-based dosing group compared to 17.56 days for the scheduled taper group, resulting in an adjusted mean ratio of 0.91 (95% CI, 0.72-1.15). Similarly, the total length of stay for infants in the Finnegan cohort was 17.38 days with symptom-based dosing versus 19.39 days with a scheduled taper, with an adjusted mean ratio of 0.9 (95% CI, 0.69-1.16). These results suggest that the clinical utility of symptom-based dosing is heavily dependent on the specific assessment framework employed by the care team, with functional assessments pairing better with flexible dosing. Clinicians must also consider the practical limitations of intermittent medication administration. Within the symptom-based group, 35% of infants (95% CI, 25%-45%) eventually required scheduled opioid dosing because their withdrawal severity was not adequately controlled with intermittent doses alone. For hospital staff, this highlights the importance of maintaining clinical flexibility to escalate to a scheduled regimen if an infant fails to stabilize. Regarding patient safety, the researchers monitored an inpatient composite safety outcome, which remained rare across both treatment arms. In the Eat, Sleep, Console cohort, this safety outcome occurred in only 3 of 188 infants in the symptom-based dosing group and 2 of 195 infants in the scheduled opioid taper group. This safety profile reassures clinicians that adopting a symptom-based strategy does not increase the risk of adverse clinical events during the critical stabilization phase.

References

1. Gilfillan KV, Dannatt L, Stein DJ, Vythilingum B. Heroin detoxification during pregnancy: A systematic review and retrospective study of the management of heroin addiction in pregnancy. South African Medical Journal. 2018. doi:10.7196/samj.2018.v108i2.7801

2. Baldacchino A, Arbuckle K, Petrie D, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry. 2014. doi:10.1186/1471-244x-14-104

3. Devlin LA, Babineau DC, Merhar SL, et al. Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial.. JAMA. 2026. doi:10.1001/jama.2026.5782

4. Negro A, Delaruelle Z, Ivanova TA, et al. Headache and pregnancy: a systematic review. The Journal of Headache and Pain. 2017. doi:10.1186/s10194-017-0816-0

5. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment. 2007. doi:10.3310/hta11090

6. Zedler B, Mann AL, Kim M, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐analysis of safety in the mother, fetus and child. Addiction. 2016. doi:10.1111/add.13462

7. Dowell D, Ragan K, Jones CM, Baldwin G, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. MMWR Recommendations and Reports. 2022. doi:10.15585/mmwr.rr7103a1